Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria
Expert Review of Clinical Pharmacology · 03.06.2026 · 19 (6) · 499-508
DOI: 10.1080/17512433.2026.2677883 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 04.06.2026. Verfasst von Tianqiao Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical Scho…. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Antibodies, Monoclonal, Humanized, Complement C5. Die Arbeit nennt 29 Literaturangaben. Gefördert von: NSFC, National Key Research and Development Program of China, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
INTRODUCTION: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disease characterized by hemolytic anemia, bone marrow failure, and thrombosis. Some PNH patients carrying the C5 mutation (Arg885) show poor response to eculizumab and ravulizumab. AREAS COVERED: The US FDA approved PiaSky (crovalimab-akkz) on 20 June 2024, for use in adults or adolescents with PNH. It is a humanized anti-C5 monoclonal antibody, formerly known as SKY59. The main objective of this review is to examine the pharmacological properties of crovalimab and its clinical efficacy and safety. EXPERT OPINION: Crovalimab inhibits the cleavage of complement C5 into C5a and C5b by specifically binding to complement C5, thus preventing terminal complement-mediated intravascular hemolysis in patients with PNH. Based on the pivotal trials COMMODORE 1 and COMMODORE 2, crovalimab had clinical efficacy not inferior to that of eculizumab and exhibited good tolerability and safety, including in controlling hemolysis, avoiding transfusions, and reducing or maintaining lactate dehydrogenase levels. Additionally, crovalimab showed a favorable response in PNH patients carrying C5 variants, and the response in adolescents aged ≥13 years was similar to that in adults. Common adverse events associated with crovalimab include infusion-related reactions, respiratory tract infections, and Type III hypersensitivity reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
- The First Affiliated Hospital, Hengyang Clinical Pharmacology Research Center, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
- The First Affiliated Hospital, Hengyang Key Laboratory of Clinical Pharmacology, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
- The First Affiliated Hospital, Department of Pharmacy, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
- MOE Key Laboratory of Pediatric Rare Diseases, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
- School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
ORCID-Profile: Tianqiao Zhang, Bo Xu, Jiecan Zhou
Förderung
- NSFC
- National Key Research and Development Program of China
- Natural Science Foundation of Hunan Province
- Hunan Provincial Health High-Level Talent Scientific Research Project
- Hunan Provincial Key Research and Development Program
- Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases
- Hunan Clinical Medical Research Center for Obesity Related Diseases
- the Science and Technology Innovation Program of Hunan Province
Zitieren
APA
Zhang, T., Xu, B., Chen, J., & Zhou, J. (2026). Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Review of Clinical Pharmacology, 19(6), 499-508. https://doi.org/10.1080/17512433.2026.2677883
Vancouver
Zhang T, Xu B, Chen J, Zhou J. Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Review of Clinical Pharmacology. 2026;19(6):499-508. doi:10.1080/17512433.2026.2677883
BibTeX
@article{Zhang2026,
author = {Zhang, Tianqiao and Xu, Bo and Chen, Jixiang and Zhou, Jiecan},
title = {Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria},
journal = {Expert Review of Clinical Pharmacology},
year = {2026},
volume = {19},
number = {6},
pages = {499--508},
doi = {10.1080/17512433.2026.2677883}
}
EUVIMED